Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Randomized, Multicenter, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Subjects With Moderate to Severe Plaque Psoriasis

NCT04999839 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT04999839
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04999839 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Randomized, Multicenter, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Subjects With Moderate to Severe Plaque Psoriasis
Lead sponsor
Takeda
Phase
Phase 2
Overall status
Completed
Start date
August 11, 2021
Completion date
September 12, 2022
Enrollment
259 (actual)
Sites
69

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe plaque psoriasis